ARTICLE | Clinical News
Acelarin: Phase I/II final data
June 8, 2015 7:00 AM UTC
Final data from an open-label, U.K. Phase I/II trial in 49 evaluable patients with advanced solid tumors showed that IV Acelarin led to a disease control rate (DCR) of 78%, including 5 partial respons...